Exelixis
King of Prussia, Pennsylvania, United States
Vicki L. Goodman, MD, has served as Executive VP, Product Development & Medical Affairs, and Chief Medical Officer since January 2022. Dr. Goodman has more than two decades of oncology experience as a drug development leader at global biopharmaceutical organizations, regulator and clinician. Prior to joining Exelixis, from June 2020 to December 2021 she was VP, Clinical Research and Therapeutic Area Head, Late Stage Oncology at Merck. Previously, from January 2015 to May 2020, Dr. Goodman served at Bristol Myers Squibb, most recently as VP and Head, New Asset Development Teams and Development Lead for Opdivo/Yervoy in melanoma and GU tumors. Prior to entering the biopharmaceutical industry, from 2004 to 2007 Dr. Goodman worked as a Medical Officer in the Division of Oncology Drug Products, part of the Center for Drug Evaluation and Research at the US FDA. From 2001 to 2004, she completed a clinical fellowship in hematology and medical oncology at the University of Michigan, Ann Arbor, where she undertook her internship and residency. Dr. Goodman obtained her MD from Albert Einstein College of Medicine and her BA in Biochemistry from Rutgers University
Disclosure information not submitted.